Secukinumab resolves bullous pemphigoid: case study
The report is the first to show successful treatment with the monoclonal antibody in a patient with concomitant bullous disorder and psoriasis
Australian clinicians have reported the first case of “dramatic” clinical improvement of active bullous pemphigoid in a patient with chronic severe psoriasis who was treated with secukinumab.
According to the Royal Melbourne Hospital-led team, the 68-year-old male patient achieved complete resolution of the bullous disorder and a reduction in Psoriasis Area and Severity Index (PASI) score ranging from 30-45 down to 0.3.
